Lonza will initiate cell line and process development for Athera’s monoclonal antibody PC-mAb. Athera’s PC-mAb is intended for the treatment of patients with Acute Coronary Syndrome who are at an increased risk of secondary cardiovascular events and death.
This agreement secures a development and cGMP manufacturing plan for Athera. Lonza will initiate cell line and process development, using Lonza’s GS Gene Expression SystemTM.
“Lonza is pleased to continue our support of emerging biotech companies with this commitment to Athera’s promising pipeline,” said Stephan Kutzer, head of Lonza’s Custom Manufacturing Division. “The PC-mAb project from Athera fits well with Lonza’s core competencies and technical experience.”
Source: Lonza
© FoodBev Media Ltd 2024